PharmaEssentia (6446.TW) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan · ISIN TW0006446008

Price
1,200.00 TWD
Market cap
495.74 bn TWD
P/E (2025)
87.98
P/S (2025)
31.71
Dividend yield
0.12 %
Net margin
32.27 %
Return on equity (ROE)
15.78 %
Return on assets (ROA)
13.49 %

PharmaEssentia financials

Fiscal year20242025
Revenue9.73 bn TWD15.63 bn TWD
Gross profit8.56 bn TWD13.68 bn TWD
Operating income1.74 bn TWD4.93 bn TWD
EBIT3.02 bn TWD5.01 bn TWD
Net income2.97 bn TWD5.05 bn TWD
Diluted EPS – continuing operations8.17 TWD13.64 TWD

Full history since 2010, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About PharmaEssentia

PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 15.10.2026. Details in the risk notice.

PharmaEssentia stock (6446.TW): P/E, revenue, dividend | finmetric